Si-bone, inc. announces publication of five-year prospective study results on 103 patients treated with triangular titanium ifuse implant system
Si-bone, inc. announced the publication of 5-year results from a long-term prospective study called lois (long term outcomes from insite and sifi). the publication, titled long-term prospective clinical and radiographic outcomes after minimally invasive lateral transiliac sacroiliac joint fusion using triangular titanium implants1 reports 5-year outcomes from a subset of patients who participated in insite (investigation of sacroiliac fusion treatment), a u.s. randomized controlled trial and sifi (sacroiliac joint fusion with ifuse implant system)3, a prospective multicenter trial. the lois study included 103 subjects treated at 12 centers who were diagnosed with sacroiliac (si) joint dysfunction and underwent si joint fusion with the ifuse implant in either of the two feeder studies (insite and sifi). study subjects were evaluated at study start (approximately 2 years after surgery) and again at 3, 4 and 5 years postoperatively. 5-year follow-up was obtained for 93 study subjects (90%) with no loss to follow-up between year 3 to 5. mean si joint pain scores decreased 54 points from baseline prior to surgery with ifuse (0–100 point scale). disability scores (oswestry disability index) decreased 26 points (0–100 scale) and quality of life improved 0.29 points (0 – 1 scale) all of which are statistically significant, clinically meaningful and consistent with previously published lois 3-year and 4-year results. the five year results from lois demonstrated that improvements in pain, patient function and quality of life demonstrated at 2-years in insite and sifi were durable and sustained at 5 years (figures 1 and 2). independent radiographic analysis of ct scans at 5 years showed a high rate of bony apposition to implants on both the sacral and iliac sides (98%) as well as a high rate of si joint fusion (88% bridging bone). patient satisfaction remained high for patients treated with the ifuse implant. there were no reported adverse events related to the study device or procedure at 5 years.
SIBN Ratings Summary
SIBN Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission